CML Treatment: Scenarios that Necessitate Switching Therapy
Jorge E. Cortes, MD, details clinical scenarios that indicate a need to switch therapies for patients with chronic myeloid leukemia.
EP: 1.Understanding CML: Your Journey from Diagnosis to Treatment
EP: 2.Navigating CML: Tools to Empower Patients and Caregivers
EP: 3.Empowering CML Caregivers: Strategies and Support Systems
EP: 4.Starting CML Treatment: Collaborative Choices for Better Outcomes
EP: 5.Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
EP: 6.When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
Now Viewing
EP: 7.CML Treatment: Scenarios that Necessitate Switching Therapy
EP: 8.Ensuring Informed CML Care from Diagnosis Onward
EP: 9.Advancing CML Management Towards an Ideal Patient Journey
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following:
- In which scenarios do you consider switching CML therapies, and how do you approach that conversation with patients? How does the patient experience change when switching therapies?
Recent Videos
Related Content
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia
Muhammad Hamza Gul, MBBS, MD;Aisha Rehman Siddiqui, MBBS, MD;Farwa Zehra, MBBS;Malaika Rehmani, MBBS;Faraz Waheed, MBBS;Natasha Masood, MBBS;Maleeha Saqib, MBBS;Mahnoor Keen, MBBS, MD;Sharan Siddharth Keshetty, MD;Maham Maqsood, MBBS;Siddharth Arjun Atwal, MD;Muhammad Hamza Sikandari, MBBS;Abdul Baseer Wardak, MBBS
August 19th 2024Article
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
